{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Systemic and ophthalmic beta-blockers. (Administer with caution as systemic', 'beta-blockers block the pulmonary effect of beta-agonists, and may produce severe', 'bronchospasm in participants with reversible obstructive airways disease.', 'Cardioselective beta-blockers should be considered, although they also should be', 'administered with caution)', 'Smoking cessation treatments', 'Cough suppressants', 'Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs). (Administer', 'with extreme caution as they may potentiate the effects of beta-agonists on the', 'cardiovascular system, including QT interval corrected for heart rate [QTc]', 'prolongation)', 'Diuretics. (Caution is advised in the co-administration of beta-agonists with non-', 'potassium sparing diuretics as this may result in electrocardiogram [ECG] changes', 'and/or hypokalemia)', 'Use of positive airway pressure for sleep apnea', 'Oral muscarinic antagonists for the treatment of overactive bladder are permitted', 'but should be used with caution as they may exacerbate medical conditions that are', 'contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder', 'outflow obstruction)', 'Cytochrome P450 (CYP)3A4 inhibitors. (Caution should be exercised when', 'considering the coadministration of long-term ketoconazole and other known', 'strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir,', 'itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin,', 'troleandomycin, voriconazole) because increased systemic corticosteroid and', 'increased cardiovascular adverse effects may occur)', '7.7.2.', 'Prohibited Medications and Non-Drug Therapies', 'Use of the medications listed in Table 4 is not permitted during the study.', 'Table 4', 'Concomitant Medications', 'Medication Prohibited during the randomised treatment period', 'Inhaled short-acting anticholinergics', 'Inhaled short-acting beta2 agonists', '1', 'Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products', 'Inhaled corticosteroids (ICS)', '55']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Medication Prohibited during the randomised treatment period', 'Inhaled corticosteroids (ICS)/Inhaled long-acting beta2-agonist (LABA) combinations', '(eg fluticasone/salmeterol, mometasone furoate/formoterol fumarate, budesonide/formoterol fumarate;', 'fluticasone furoate/vilanterol', 'Phosphodiesterase 4 (PDE4) inhibitors (roflumilast)', 'LABA (e.g., indacaterol, olodaterol, salmeterol etc.)', 'Other LAMAs (aclidinium, glycopyrronium, umeclidinium etc.)', 'LAMA/LABA combinations', 'Theophyllines', 'Sodium cromoglycate and nedocromil sodium', 'Anti-leukotrienes', 'Long term antibiotic therapy 2', 'Systemic, oral, parenteral corticosteroids 3', 'Any other investigational drug', '1 (rescue albuterol/salbutamol will be provided and is permitted during the study)', '2 (Antibiotics are allowed for the short term treatment (<14 days) of an exacerbation or for short term', 'treatment (<14 days) of other acute infections during the study)', '3 (During the study oral/systemic corticosteroids may be used for <14 days to treat COPD', 'exacerbations/pneumonia) Intra-articular injections are allowed.', 'Note: Topical and ophthalmic corticosteroids, and localized corticosteroid injections', '(intra-articular and epidural) are allowed.', 'NOTE: All COPD medications (except for rescue albuterol/salbutamol, mucolytics and', 'oxygen) are prohibited during the run-in and randomised treatment periods of the study', 'except during the treatment of a moderate/severe COPD exacerbation or pneumonia. In', 'the event of an exacerbation or pneumonia, sites should attempt to follow protocol', 'treatment guidelines, however, treatment with any medication that the health care', 'provider deems necessary is allowed. Caution is advised in using a LABA or LAMA to', 'treat a participant currently taking study treatment as these additional medications may', 'increase the risk of overdose. If necessary the Investigator or other health care', \"personnel may stop the participant's study treatment temporarily (<14 days) in order to\", 'treat the COPD exacerbation or pneumonia. Participants who require more than two', 'consecutive 14 day courses of treatment (i.e. antibiotics or corticosteroids) should be', 'evaluated for their continuation on study treatment by the Investigator in consultation', 'with the GSK medical monitor.', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', '56']\n\n###\n\n", "completion": "END"}